Financials data is unavailable for this security.
View more
Year on year Avidity Biosciences Inc had net income fall 21.97% from a loss of 174.00m to a larger loss of 212.22m despite a 3.64% increase in revenues from 9.22m to 9.56m. An increase in the selling, general and administrative costs as a percentage of sales from 409.07% to 566.84% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -2,381.82% |
| Operating margin | -2,690.64% |
| Return on assets | -25.78% |
|---|---|
| Return on equity | -28.36% |
| Return on investment | -27.61% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Avidity Biosciences Inc fell by 155.27m. Cash Flow from Financing totalled 93.86m or 981.84% of revenues. In addition the company used 119.06m for operations while cash used for investing totalled 130.07m.
| Cash flow per share | -2.90 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 11.17 |
|---|---|
| Tangible book value per share | 11.17 |
More ▼
Balance sheet in USDView more
| Current ratio | 15.78 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
